{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T01:59:19Z","timestamp":1793411959750,"version":"4.5.0"},"reference-count":166,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T00:00:00Z","timestamp":1775606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T00:00:00Z","timestamp":1775606400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1038\/s41375-026-02882-w","type":"journal-article","created":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T12:15:15Z","timestamp":1775650515000},"page":"1122-1136","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["A paradigm shift in the treatment of patients with polycythemia vera. The initial early use of recombinant interferon-alpha"],"prefix":"10.1038","volume":"40","author":[{"given":"Richard T.","family":"Silver","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3936-8032","authenticated-orcid":false,"given":"Hans Carl","family":"Hasselbalch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,8]]},"reference":[{"key":"2882_CR1","doi-asserted-by":"publisher","first-page":"3065","DOI":"10.1182\/blood-2008-03-143537","volume":"112","author":"JJ Kiladjian","year":"2008","unstructured":"Kiladjian JJ, Cassinat B, Chevret S, Turlure P, Cambier N, Roussel M, et al. Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood. 2008;112:3065\u201372.","journal-title":"Blood"},{"key":"2882_CR2","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1016\/j.leukres.2013.06.012","volume":"37","author":"TS Larsen","year":"2013","unstructured":"Larsen TS, Iversen KF, Hansen E, Mathiasen AB, Marcher C, Frederiksen M, et al. Long-term molecular responses in a cohort of Danish patients with essential thrombocythemia, polycythemia vera and myelofibrosis treated with recombinant interferon alpha. Leuk Res. 2013;37:1041\u20135.","journal-title":"Leuk Res"},{"key":"2882_CR3","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1182\/blood-2012-07-442012","volume":"122","author":"A Quintas-Cardama","year":"2013","unstructured":"Quintas-Cardama A, Abdel-Wahab O, Manshouri T, Kilpivaara O, Cortes J, Roupie AL, et al. Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon alpha-2a. Blood. 2013;122:893\u2013901.","journal-title":"Blood"},{"key":"2882_CR4","doi-asserted-by":"publisher","first-page":"e165","DOI":"10.1016\/S2352-3026(17)30030-3","volume":"4","author":"L Masarova","year":"2017","unstructured":"Masarova L, Patel KP, Newberry KJ, Cortes J, Borthakur G, Konopleva M, et al. Pegylated interferon alfa-2a in patients with essential thrombocythaemia or polycythaemia vera: a post-hoc, median 83-month follow-up of an open-label, phase 2 trial. Lancet Haematol. 2017;4:e165\u2013e175.","journal-title":"Lancet Haematol"},{"key":"2882_CR5","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1038\/leu.2015.326","volume":"30","author":"JJ Kiladjian","year":"2016","unstructured":"Kiladjian JJ, Giraudier S, Cassinat B. Interferon-alpha for the therapy of myeloproliferative neoplasms: targeting the malignant clone. Leukemia. 2016;30:776\u201381.","journal-title":"Leukemia"},{"key":"2882_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-018-0133-0","volume":"8","author":"E Verger","year":"2018","unstructured":"Verger E, Soret-Dulphy J, Maslah N, Roy L, Rey J, Ghrieb Z, et al. Ropeginterferon alpha-2b targets JAK2V617F-positive polycythemia vera cells in vitro and in vivo. Blood Cancer J. 2018;8:94.","journal-title":"Blood Cancer J"},{"key":"2882_CR7","doi-asserted-by":"publisher","first-page":"3692","DOI":"10.1182\/blood-2012-05-432989","volume":"121","author":"A Mullally","year":"2013","unstructured":"Mullally A, Bruedigam C, Poveromo L, Heidel FH, Purdon A, Vu T, et al. Depletion of Jak2V617F myeloproliferative neoplasm-propagating stem cells by interferon-\u03b1 in a murine model of polycythemia vera. Blood. 2013;121:3692\u2013702.","journal-title":"Blood"},{"key":"2882_CR8","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1182\/blood.2021010986","volume":"138","author":"M Mosca","year":"2021","unstructured":"Mosca M, Hermange G, Tisserand A, Noble R, Marzac C, Marty C, et al. Inferring the dynamics of mutated hematopoietic stem and progenitor cells induced by IFN\u03b1 in myeloproliferative neoplasms. Blood. 2021;138:2231\u201343.","journal-title":"Blood"},{"key":"2882_CR9","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1182\/blood.2020005563","volume":"137","author":"TN Rao","year":"2021","unstructured":"Rao TN, Hansen N, Stetka J, Luque Paz D, Kalmer M, Hilfiker J, et al. JAK2-V617F and interferon-\u03b1 induce megakaryocyte-biased stem cells characterized by decreased long-term functionality. Blood 2021;137:2139-51.","journal-title":"Blood"},{"key":"2882_CR10","doi-asserted-by":"publisher","first-page":"348","DOI":"10.3109\/10428194.2015.1049171","volume":"57","author":"C Utke Rank","year":"2016","unstructured":"Utke Rank C, Weis Bjerrum O, Larsen TS, Kjaer L, de Stricker K, Riley CH, et al. Minimal residual disease after long-term interferon-alpha2 treatment: a report on hematological, molecular and histomorphological response patterns in 10 patients with essential thrombocythemia and polycythemia vera. Leuk Lymphoma. 2016;57:348\u201354.","journal-title":"Leuk Lymphoma"},{"key":"2882_CR11","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1182\/blood-2020-141223","volume":"136","author":"RD de Oliveira","year":"2020","unstructured":"de Oliveira RD, Soret-Dulphy J, Zhao L, Marcuault C, Gauthier N, Verger E, et al. Interferon-alpha (IFN) therapy discontinuation is feasible in myeloproliferative neoplasm (MPN) Patients with complete hematological remission. Blood. 2020;136:35\u20136.","journal-title":"Blood"},{"key":"2882_CR12","doi-asserted-by":"publisher","first-page":"e645","DOI":"10.1097\/HS9.0000000000000645","volume":"5","author":"HC Hasselbalch","year":"2021","unstructured":"Hasselbalch HC, Silver RT. New perspectives of interferon-alpha2 and inflammation in treating Philadelphia-negative chronic myeloproliferative neoplasms. Hemasphere. 2021;5:e645.","journal-title":"Hemasphere"},{"key":"2882_CR13","doi-asserted-by":"publisher","first-page":"2592","DOI":"10.1038\/s41375-021-01183-8","volume":"5","author":"G Abu-Zeinah","year":"2021","unstructured":"Abu-Zeinah G, Krichevsky S, Cruz T, Hoberman G, Jaber D, Savage N, et al. Interferon-alpha for treating polycythemia vera yields improved myelofibrosis-free and overall survival. Leukemia. 2021;5:2592\u20132601. 3.","journal-title":"Leukemia"},{"key":"2882_CR14","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1038\/s41375-025-02545-2","volume":"39","author":"Y Beauverd","year":"2025","unstructured":"Beauverd Y, Ianotto JC, Thaw KH, Sobas M, Sadjadian P, Curto-Garcia N, et al. Impact of treatment for adolescent and young adults with essential thrombocythemia and polycythemia vera. Leukemia. 2025;39:1135\u201345.","journal-title":"Leukemia"},{"key":"2882_CR15","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1016\/j.clml.2018.08.009","volume":"18","author":"MR Grunwald","year":"2018","unstructured":"Grunwald MR, Stein BL, Boccia RV, Oh ST, Paranagama D, Parasuraman S, et al. Clinical and disease characteristics from REVEAL at time of enrollment (Baseline): prospective observation study of patients with polycythemia vera in the United States. Clin Lymphoma Myeloma Leuk. 2018;18:788\u2013795.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2882_CR16","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1111\/bjh.18213","volume":"198","author":"A Tefferi","year":"2022","unstructured":"Tefferi A, Ianotto JC, Mathews V, Samuelsson J, Szuber N, Xiao Z, et al. Myeloproliferative neoplasms\u2014a global view. Br J Haematol. 2022;198:953\u2013964.","journal-title":"Br J Haematol"},{"key":"2882_CR17","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1586\/era.11.10","volume":"11","author":"JL Spivak","year":"2011","unstructured":"Spivak JL, Hasselbalch H. Hydroxycarbamide: a user\u2019s guide for chronic myeloproliferative disorders. Expert Rev Anticancer Ther. 2011;11:403\u201314.","journal-title":"Expert Rev Anticancer Ther"},{"key":"2882_CR18","doi-asserted-by":"publisher","first-page":"e301","DOI":"10.1016\/S2352-3026(22)00046-1","volume":"9","author":"M Marchetti","year":"2022","unstructured":"Marchetti M, Vannucchi AM, Griesshammer M, Harrison C, Koschmieder S, Gisslinger H, et al. Appropriate management of polycythaemia vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendations. Lancet Haematol. 2022;9:e301\u2013e311.","journal-title":"Lancet Haematol"},{"key":"2882_CR19","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.6004\/jnccn.2022.0046","volume":"20","author":"AT Gerds","year":"2022","unstructured":"Gerds AT, Gotlib J, Ali H, Bose P, Castells M, Revell RF, et al. Myeloproliferative neoplasms, version 3.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2022;20:1033\u201362.","journal-title":"J Natl Compr Cancer Netw"},{"key":"2882_CR20","unstructured":"Gerds AT, Gotlib J, Abdelmessieh P, Ali H, Bose P, Dunbar A, et al. NCCN Clinical Practice Guidelines in Oncology. Myeloproliferative Neoplasms. Version 2. 2025."},{"key":"2882_CR21","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1182\/blood-2014-07-591610","volume":"124","author":"T Barbui","year":"2014","unstructured":"Barbui T, Carobbio A, Rumi E, Finazzi G, Gisslinger H, Rodeghiero F, et al. In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology. Blood. 2014;124:3021\u20133023.","journal-title":"Blood"},{"key":"2882_CR22","doi-asserted-by":"publisher","first-page":"E5","DOI":"10.1002\/ajh.24583","volume":"92","author":"T Barbui","year":"2017","unstructured":"Barbui T, Vannucchi AM, Carobbio A, Rumi E, Finazzi G, Gisslinger H, et al. The effect of arterial hypertension on thrombosis in low-risk polycythemia vera. Am J Hematol. 2017;92:E5\u2013E6.","journal-title":"Am J Hematol"},{"key":"2882_CR23","doi-asserted-by":"publisher","first-page":"317","DOI":"10.7326\/M17-0028","volume":"168","author":"M Hultcrantz","year":"2018","unstructured":"Hultcrantz M, Bj\u00f6rkholm M, Dickman PW, Landgren O, Derolf \u00c5, Kristinsson SY, et al. Risk for arterial and venous thrombosis in patients with myeloproliferative neoplasms: a population-based cohort study. Ann Intern Med. 2018;168:317\u201325.","journal-title":"Ann Intern Med"},{"key":"2882_CR24","doi-asserted-by":"publisher","first-page":"2226","DOI":"10.3109\/10428194.2013.766732","volume":"54","author":"J Abelsson","year":"2013","unstructured":"Abelsson J, Andr\u00e9asson B, Samuelsson J, Hultcrantz M, Ejerblad E, Johansson B, et al. Patients with polycythemia vera have the worst impairment of quality of life among patients with newly diagnosed myeloproliferative neoplasms. Leuk Lymphoma. 2013;54:2226\u201330.","journal-title":"Leuk Lymphoma"},{"key":"2882_CR25","doi-asserted-by":"publisher","first-page":"112","DOI":"10.3945\/an.110.000190","volume":"2","author":"SJ Fretham","year":"2011","unstructured":"Fretham SJ, Carlson ES, Georgieff MK. The role of iron in learning and memory. Adv Nutr. 2011;2:112\u201321.","journal-title":"Adv Nutr"},{"key":"2882_CR26","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1093\/eurjhf\/hfs017","volume":"14","author":"T Avni","year":"2012","unstructured":"Avni T, Leibovici L, Gafter-Gvili A. Iron supplementation for the treatment of chronic heart failure and iron deficiency: systematic review and meta-analysis. Eur Heart Fail. 2012;14:423\u20139.","journal-title":"Eur Heart Fail"},{"key":"2882_CR27","doi-asserted-by":"publisher","first-page":"e82952","DOI":"10.1371\/journal.pone.0082952","volume":"8","author":"YL Chang","year":"2013","unstructured":"Chang YL, Hung SH, Ling W, Lin HC, Li HC, Chung SD. Association between ischemic stroke and iron-deficiency anemia: a population-based study. PLoS ONE. 2013;8:e82952.","journal-title":"PLoS ONE"},{"key":"2882_CR28","doi-asserted-by":"publisher","first-page":"661","DOI":"10.3324\/haematol.2020.270496","volume":"106","author":"H Al-Samkari","year":"2021","unstructured":"Al-Samkari H, Kessler CM, Auerbach M. Recognition of thrombotic risk of thrombocytosis in iron deficiency. Haematologica. 2021;106:661\u20133.","journal-title":"Haematologica"},{"key":"2882_CR29","doi-asserted-by":"publisher","first-page":"782","DOI":"10.3324\/haematol.2019.245092","volume":"106","author":"K Jimenez","year":"2021","unstructured":"Jimenez K, Leitner F, Leitner A, Scharbert G, Swabl P, Kramer AM, et al. Iron deficiency-induced thrombocytosis increases thrombotic tendency in rats. Haematologica. 2021;106:782\u201394.","journal-title":"Haematologica"},{"key":"2882_CR30","doi-asserted-by":"publisher","first-page":"3339","DOI":"10.1038\/s41375-021-01401-3","volume":"35","author":"A Tefferi","year":"2021","unstructured":"Tefferi A, Vannucchi AM, Barbui T. Polycythemia vera: historical oversights, diagnostic details, and therapeutic views. Leukemia. 2021;35:3339\u201351.","journal-title":"Leukemia"},{"key":"2882_CR31","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1111\/bjh.12117","volume":"160","author":"G Bonicelli","year":"2013","unstructured":"Bonicelli G, Abdulkarim K, Mounier M, Johansson P, Rossi C, Jooste V, et al. Leucocytosis and thrombosis at diagnosis are associated with poor survival in polycythaemia vera: a population-based study of 327 patients. Br J Haematol. 2013;160:251\u20134.","journal-title":"Br J Haematol"},{"key":"2882_CR32","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.3390\/ijms22031143","volume":"22","author":"F Ferrer-Mar\u00edn","year":"2021","unstructured":"Ferrer-Mar\u00edn F, Cuenca-Zamora EJ, Guijarro-Carrillo PJ, Teruel-Montoya R. Emerging role of neutrophils in the thrombosis of chronic myeloproliferative neoplasms. Int J Mol Sci. 2021;22:1143.","journal-title":"Int J Mol Sci"},{"key":"2882_CR33","doi-asserted-by":"publisher","first-page":"e175","DOI":"10.1016\/S2352-3026(20)30373-2","volume":"8","author":"T Barbui","year":"2021","unstructured":"Barbui T, Vannucchi AM, De Stefano V, Masciulli A, Carobbio A, Ferrari A, et al. Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial. Lancet Haematol. 2021;8:e175\u2013e184.","journal-title":"Lancet Haematol"},{"key":"2882_CR34","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1038\/s41375-021-01447-3","volume":"36","author":"G Abu-Zeinah","year":"2022","unstructured":"Abu-Zeinah G, Silver RT, Abu-Zeinah K, Scandura JM. Normal life expectancy for polycythemia vera (PV) patients is possible. Leukemia. 2022;36:569\u201372.","journal-title":"Leukemia"},{"key":"2882_CR35","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1089\/jir.2012.0120","volume":"33","author":"BL Stein","year":"2013","unstructured":"Stein BL, Tiu RV. Biological rationale and clinical use of interferon in the classical BCR-ABL-negative myeloproliferative neoplasms. J Interferon Cytokine Res. 2013;33:145\u201353.","journal-title":"J Interferon Cytokine Res"},{"key":"2882_CR36","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/s41573-018-0011-2","volume":"18","author":"EC Borden","year":"2019","unstructured":"Borden EC. Interferons \u03b1 and \u03b2 in cancer: therapeutic opportunities from new insights. Nat Rev Drug Discov. 2019;18:219\u201334.","journal-title":"Nat Rev Drug Discov"},{"key":"2882_CR37","doi-asserted-by":"publisher","first-page":"3857","DOI":"10.1016\/j.cell.2022.09.023","volume":"185","author":"RL Philips","year":"2022","unstructured":"Philips RL, Wang Y, Cheon H, Kanno Y, Gadina M, Sartorelli V, et al. The JAK-STAT pathway at 30: much learned, much more to do. Cell. 2022;185:3857\u201376.","journal-title":"Cell"},{"key":"2882_CR38","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1038\/s41375-025-02569-8","volume":"39","author":"F Perner","year":"2025","unstructured":"Perner F, Pahl HL, Zeiser R, Heidel FH. Malignant JAK-signaling: at the interface of inflammation and malignant transformation. Leukemia. 2025;39:1011\u201330.","journal-title":"Leukemia"},{"key":"2882_CR39","doi-asserted-by":"publisher","first-page":"2170","DOI":"10.1182\/blood-2011-03-340992","volume":"118","author":"CH Riley","year":"2011","unstructured":"Riley CH, Jensen MK, Brimnes MK, Hasselbalch HC, Bjerrum OW, Straten PT, et al. Increase in circulating CD4\u207aCD25\u207aFoxp3\u207a T cells in patients with Philadelphia-negative chronic myeloproliferative neoplasms during treatment with IFN-\u03b1. Blood. 2011;118:2170\u20133.","journal-title":"Blood"},{"key":"2882_CR40","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1111\/ejh.12420","volume":"94","author":"CH Riley","year":"2015","unstructured":"Riley CH, Hansen M, Brimnes MK, Hasselbalch HC, Bjerrum OW, Straten PT, et al. Expansion of circulating CD56bright natural killer cells in patients with JAK2-positive chronic myeloproliferative neoplasms during treatment with interferon-\u03b1. Eur J Haematol. 2015;94:227\u201334.","journal-title":"Eur J Haematol"},{"key":"2882_CR41","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/ejh.12687","volume":"97","author":"CH Riley","year":"2016","unstructured":"Riley CH, Brimnes MK, Hansen M, Jensen MK, Hasselbalch HC, Kjaer L, et al. Interferon-\u03b1 induces marked alterations in circulating regulatory T cells, NK cell subsets, and dendritic cells in patients with JAK2V617F-positive essential thrombocythemia and polycythemia vera. Eur J Haematol. 2016;97:83\u201392.","journal-title":"Eur J Haematol"},{"key":"2882_CR42","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1080\/10428194.2016.1262032","volume":"58","author":"V Skov","year":"2017","unstructured":"Skov V, Riley CH, Thomassen M, Kj\u00e6r L, Stauffer Larsen T, Bjerrum OW, et al. The impact of interferon-alpha2 on HLA genes in patients with polycythemia vera and related neoplasms. Leuk Lymphoma. 2017;58:1914\u201321.","journal-title":"Leuk Lymphoma"},{"key":"2882_CR43","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1182\/blood.V96.6.2093","volume":"96","author":"Q Wang","year":"2000","unstructured":"Wang Q, Miyakawa Y, Fox N, Kauschansky K. Interferon-\u03b1 directly represses megakaryopoiesis by inhibiting thrombopoietin-induced signaling through induction of SOCS-1. Blood. 2000;96:2093\u20139.","journal-title":"Blood"},{"key":"2882_CR44","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.1182\/blood.2019000162","volume":"134","author":"TN Rao","year":"2019","unstructured":"Rao TN, Hansen N, Hilfiker J, Rai S, Majewska JM, Lekovic D, et al. JAK2-mutant hematopoietic cells display metabolic alterations that can be targeted to treat myeloproliferative neoplasms. Blood. 2019;134:1832\u201346.","journal-title":"Blood"},{"key":"2882_CR45","doi-asserted-by":"crossref","unstructured":"Skov V. Next-generation sequencing in MPNs. lessons from the past and prospects for use as predictors of prognosis and treatment responses. Cancers. 2020;12:2194.","DOI":"10.3390\/cancers12082194"},{"key":"2882_CR46","unstructured":"Kralovics R, Klade C, Georgiev P, Krochmalczyk D, Gercheva-Kyuchukova L, Egyed M et al. Ropeinterferon alpha-2b is efficacious and reduces variant TET2 allele burden in patients with polycythemia vera and TET2 mutation: genetic analysis of phase III PROUD-PV\/ CONTINUATION-PV STUDIES; EHA Library. 06\/12\/2020; 293574; EP1085."},{"key":"2882_CR47","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1182\/blood-2018-99-118715","volume":"132","author":"H Gisslinger","year":"2018","unstructured":"Gisslinger H, Klade C, Georgiev P, Krochmalczyk D, Gercheva-Kyuchukova L, Egyed M, et al. Evidence for superior efficacy and disease modification after three years of prospective randomized controlled treatment of polycythemia vera patients with ropeginterferon alfa-2b vs. HU\/BAT. Blood. 2018;132:579.","journal-title":"Blood"},{"key":"2882_CR48","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1038\/leu.2010.120","volume":"24","author":"JJ Kiladjian","year":"2010","unstructured":"Kiladjian JJ, Mass\u00e9 A, Cassinat B, Mokrani H, Teyssandier I, le Cou\u00e9dic JP, et al. French intergroup of myeloproliferative neoplasms (FIM). Clonal analysis of erythroid progenitors suggests that pegylated interferon alpha-2a treatment targets JAK2V617F clones without affecting TET2 mutant cells. Leukemia. 2010;24:1519\u201323.","journal-title":"Leukemia"},{"key":"2882_CR49","doi-asserted-by":"publisher","first-page":"2680","DOI":"10.1002\/cncr.30679","volume":"123","author":"RT Silver","year":"2017","unstructured":"Silver RT, Barel AC, Lascu E, Ritchie EK, Roboz GJ, Christos PJ, et al. The effect of initial molecular profile on response to recombinant interferon-\u03b1 (rIFN\u03b1) treatment in early myelofibrosis. Cancer. 2017;123:2680\u20137.","journal-title":"Cancer"},{"key":"2882_CR50","doi-asserted-by":"publisher","first-page":"438","DOI":"10.3324\/haematol.2017.181297","volume":"103","author":"JC Ianotto","year":"2018","unstructured":"Ianotto JC, Chauveau A, Boyer-Perrard F, Gyan E, Laribi K, Cony-Makhoul P, et al. Benefits and pitfalls of pegylated interferon-\u03b12a therapy in patients with myeloproliferative neoplasm-associated myelofibrosis: a French Intergroup of Myeloproliferative neoplasms (FIM) study. Haematologica. 2018;103:438\u201346.","journal-title":"Haematologica"},{"key":"2882_CR51","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.1182\/bloodadvances.2021004856","volume":"6","author":"TA Knudsen","year":"2022","unstructured":"Knudsen TA, Skov V, Stevenson K, Werner L, Duke W, Laurore C, et al. Genomic profiling of a randomized trial of interferon-\u03b1 vs hydroxyurea in MPN reveals mutation-specific responses. Blood Adv. 2022;6:2107\u201319.","journal-title":"Blood Adv"},{"key":"2882_CR52","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1182\/blood.2024027528","volume":"146","author":"G Abu-Zeinah","year":"2025","unstructured":"Abu-Zeinah G, Erdos K, Lee N, Ganom Y, Klade C, Krejcy K, et al. DNMT3A mutations are unlikely to affect interferon alfa treatment outcomes in patients with polycythemia vera. Blood. 2025;146:123\u20136.","journal-title":"Blood"},{"key":"2882_CR53","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1038\/s41375-023-01886-0","volume":"37","author":"N Maslah","year":"2023","unstructured":"Maslah N, Benajiba L, Giraudier S, Kiladjian JJ, Cassinat B. Clonal architecture evolution in myeloproliferative neoplasms: from a driver mutation to a complex heterogeneous mutational and phenotypic landscape. Leukemia. 2023;37:957\u201363.","journal-title":"Leukemia"},{"key":"2882_CR54","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1384509","volume":"15","author":"TI Boklund","year":"2024","unstructured":"Boklund TI, Snyder J, Gudmand-Hoeyer J, Larsen MK, Knudsen TA, Eickhardt-Dalb\u00f8ge CS, et al. Mathematical modelling of stem and progenitor cell dynamics during ruxolitinib treatment of patients with myeloproliferative neoplasms. Front Immunol. 2024;15:1384509.","journal-title":"Front Immunol"},{"key":"2882_CR55","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1182\/blood-2016-10-696005","volume":"129","author":"AJ Mead","year":"2017","unstructured":"Mead AJ, Mullally A. Myeloproliferative neoplasm stem cells. Blood. 2017;129:1607\u201316.","journal-title":"Blood"},{"key":"2882_CR56","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1182\/blood.2022017416","volume":"141","author":"J How","year":"2023","unstructured":"How J, Garcia JS, Mullally A. Biology and therapeutic targeting of molecular mechanisms in MPNs. Blood. 2023;141:1922\u201333.","journal-title":"Blood"},{"key":"2882_CR57","doi-asserted-by":"crossref","unstructured":"Austin RJ, Straube J, Bruedigam C, Pali G, Jacquelin S, Vu T, et al. Distinct effects of ruxolitinib and interferon-alpha on murine JAK2V617F myeloproliferative neoplasm hematopoietic stem cell populations. Leukemia 2020;34:1075\u201389.","DOI":"10.1038\/s41375-019-0638-y"},{"key":"2882_CR58","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1080\/17474086.2017.1284583","volume":"10","author":"ME Bj\u00f8rn","year":"2017","unstructured":"Bj\u00f8rn ME, Hasselbalch HC. Minimal residual disease or cure in MPNs? Rationales and perspectives on combination therapy with interferon-alpha2 and ruxolitinib. Expert Rev Hematol. 2017;10:393\u2013404.","journal-title":"Expert Rev Hematol"},{"key":"2882_CR59","doi-asserted-by":"publisher","first-page":"5416","DOI":"10.1182\/bloodadvances.2024013170","volume":"8","author":"AL S\u00f8rensen","year":"2024","unstructured":"S\u00f8rensen AL, Skov V, Kj\u00e6r L, Bj\u00f8rn ME, Eickhardt-Dalb\u00f8ge CS, Larsen MK, et al. Combination therapy with ruxolitinib and pegylated interferon alfa-2a in newly diagnosed patients with polycythemia vera. Blood Adv. 2024;8:5416\u201325.","journal-title":"Blood Adv"},{"key":"2882_CR60","doi-asserted-by":"publisher","first-page":"315","DOI":"10.2165\/00063030-200822050-00004","volume":"22","author":"FM Veronese","year":"2008","unstructured":"Veronese FM, Mero A. The impact of PEGylation on biological therapies. BioDrugs. 2008;22:315\u20139.","journal-title":"BioDrugs"},{"key":"2882_CR61","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1080\/17425255.2021.1839050","volume":"17","author":"\u00c1 Ill\u00e9s","year":"2021","unstructured":"Ill\u00e9s \u00c1, Pincz\u00e9s LI, Egyed M. A pharmacokinetic evaluation of ropeginterferon alfa-2b in the treatment of polycythemia vera. Expert Opin Drug Metab Toxicol. 2021;17:3\u20137.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"2882_CR62","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2025.108110","volume":"158","author":"N Lee Jr","year":"2025","unstructured":"Lee N Jr, Erdos K, Rahman AA, Silver RT, Scandura JM, et al. Low-dose ropeginterferon alfa-2b and peginterferon alfa-2a have comparable efficacy and tolerability in polycythemia vera. Leuk Res. 2025;158:108110.","journal-title":"Leuk Res"},{"key":"2882_CR63","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1038\/s41375-020-0945-3","volume":"35","author":"F Stegelmann","year":"2021","unstructured":"Stegelmann F, Wille K, Busen H, Fuchs C, Schauer S, Sadjadian P, et al. Significant association of cutaneous adverse events with hydroxyurea: results from a prospective non-interventional study in BCR-ABL1-negative myeloproliferative neoplasms (MPN)\u2014on behalf of the German Study Group-MPN. Leukemia. 2021;35:628\u201331.","journal-title":"Leukemia"},{"key":"2882_CR64","doi-asserted-by":"publisher","first-page":"4706","DOI":"10.1182\/blood-2010-08-258772","volume":"117","author":"JJ Kiladjian","year":"2011","unstructured":"Kiladjian JJ, Mesa RA, Hoffman R. The renaissance of interferon therapy for the treatment of myeloid malignancies. Blood. 2011;117:4706\u201315.","journal-title":"Blood"},{"key":"2882_CR65","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1038\/s41375-020-01020-4","volume":"35","author":"JP Bewersdorf","year":"2021","unstructured":"Bewersdorf JP, Giri S, Wang R, Podoltsev N, Williams RT, Tallman MS, et al. Interferon alpha therapy in essential thrombocythemia and polycythemia vera\u2014a systematic review and meta-analysis. Leukemia. 2021;35:1643\u201360.","journal-title":"Leukemia"},{"key":"2882_CR66","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.6004\/jnccn.2022.7026","volume":"20","author":"J How","year":"2022","unstructured":"How J, Hobbs G. Interferons as the first choice of cytoreduction in essential thrombocythemia and polycythemia vera. J Natl Compr Canc Netw. 2022;20:1063\u201368.","journal-title":"J Natl Compr Canc Netw"},{"key":"2882_CR67","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1182\/blood.2023021503","volume":"142","author":"JP Bewersdorf","year":"2023","unstructured":"Bewersdorf JP, How J, Masarova L, Bose P, Pemmaraju N, Mascarenhas JO, et al. Moving towards disease modification in polycythemia vera. Blood. 2023;142:1859\u201370.","journal-title":"Blood"},{"key":"2882_CR68","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1182\/hematology.2024000577","volume":"2024","author":"JJ Kiladjian","year":"2024","unstructured":"Kiladjian JJ. Pegylated interferon: the who, why, and how. Hematol Am Soc Hematol Educ Program. 2024;2024:535\u201340.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"2882_CR69","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1080\/17474086.2023.2198698","volume":"16","author":"RT Silver","year":"2023","unstructured":"Silver RT, Abu-Zeinah G. Polycythemia vera: aspects of its current diagnosis and initial treatment. Expert Rev Hematol. 2023;16:253\u201366.","journal-title":"Expert Rev Hematol"},{"key":"2882_CR70","doi-asserted-by":"publisher","first-page":"E47.","DOI":"10.1038\/s41586-023-06375-z","volume":"619","author":"WJ Wong","year":"2023","unstructured":"Wong WJ, Emdin C, Bick AG, Zekavat SM, Niroula A, Pirruccello JP, et al. NHLBI TOPMed Hematology Working Group; Ebert BL, Natarajan P. Clonal haematopoiesis and risk of chronic liver disease. Nature. 2023;619:E47.","journal-title":"Nature"},{"key":"2882_CR71","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1111\/bjh.15648","volume":"184","author":"MF McMullin","year":"2018","unstructured":"McMullin MF, Harrison CN, Ali S, Cargo C, Chen F, Ewing J, et al. A guideline for the diagnosis and management of polycythaemia vera. A British Society for Haematology guideline. Br J Haematol. 2018;184:176\u201391.","journal-title":"Br J Haematol"},{"key":"2882_CR72","doi-asserted-by":"publisher","first-page":"204062072412295","DOI":"10.1177\/20406207241229588","volume":"15","author":"P Vachhani","year":"2024","unstructured":"Vachhani P, Mascarenhas J, Bose P, Hobbs G, Yacoub A, Palmer JM, et al. Interferons in the treatment of myeloproliferative neoplasms. Ther Adv Hematol. 2024;15:20406207241229588 https:\/\/doi.org\/10.1177\/20406207241229588.","journal-title":"Ther Adv Hematol"},{"key":"2882_CR73","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41572-025-00608-3","volume":"11","author":"CN Harrison","year":"2025","unstructured":"Harrison CN, Barbui T, Bose P, Kiladjian JJ, Mascarenhas J, McMullin MF, et al. Polycythaemia vera. Nat Rev Dis Primers. 2025;11:26.","journal-title":"Nat Rev Dis Primers"},{"key":"2882_CR74","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1109866","volume":"13","author":"A Qin","year":"2023","unstructured":"Qin A, Urbanski RW, Yu L, Ahmed T, Mascarenhas J. An alternative dosing strategy for ropeginterferon alfa-2b may help improve outcomes in myeloproliferative neoplasms: an overview of previous and ongoing studies with perspectives on the future. Front Oncol. 2023;13:1109866. https:\/\/doi.org\/10.3389\/fonc.2023.1109866.","journal-title":"Front Oncol"},{"key":"2882_CR75","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1200\/JCO.2005.07.062","volume":"23","author":"R Marchioli","year":"2005","unstructured":"Marchioli R, Finazzi G, Landolfi R, Kutti J, Gisslinger H, Patrono C, et al. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol. 2005;23:2224\u201332.","journal-title":"J Clin Oncol"},{"key":"2882_CR76","doi-asserted-by":"publisher","first-page":"106809","DOI":"10.1016\/j.leukres.2022.106809","volume":"115","author":"N Pemmaraju","year":"2022","unstructured":"Pemmaraju N, Gerds AT, Yu J, Parasuraman S, Shah A, Xi A, et al. Thrombotic events and mortality risk in patients with newly diagnosed polycythemia vera or essential thrombocythemia. Leuk Res. 2022;115:106809.","journal-title":"Leuk Res"},{"key":"2882_CR77","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.1182\/blood.2020008109","volume":"137","author":"HC Hasselbalch","year":"2021","unstructured":"Hasselbalch HC, Elvers M, Schafer AI. The pathobiology of thrombosis, microvascular disease, and hemorrhage in the myeloproliferative neoplasms. Blood. 2021;137:2152\u201360.","journal-title":"Blood"},{"key":"2882_CR78","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1182\/blood.2020008043","volume":"137","author":"AR Moliterno","year":"2021","unstructured":"Moliterno AR, Ginzburg YZ, Hoffman R. Clinical insights into the origins of thrombosis in myeloproliferative neoplasms. Blood. 2021;137:1145\u201353.","journal-title":"Blood"},{"key":"2882_CR79","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1182\/blood.2022017697","volume":"141","author":"AR Moliterno","year":"2023","unstructured":"Moliterno AR, Kaizer H, Reeves BN. JAK2 V617F allele burden in polycythemia vera: burden of proof. Blood. 2023;141:1934\u201342.","journal-title":"Blood"},{"key":"2882_CR80","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1038\/leu.2010.148","volume":"24","author":"F Passamonti","year":"2010","unstructured":"Passamonti F, Rumi E, Pietra D, Elena C, Boveri E, Arcaini L, et al. A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. Leukemia. 2010;24:1574\u20139.","journal-title":"Leukemia"},{"key":"2882_CR81","doi-asserted-by":"publisher","first-page":"85","DOI":"10.7150\/ijms.10539","volume":"13","author":"S Zhao","year":"2016","unstructured":"Zhao S, Zhang X, Xu Y, Feng Y, Sheng W, Cen J, et al. Impact of JAK2V617F mutation burden on disease phenotype in Chinese patients with JAK2V617F-positive polycythemia vera (PV) and essential thrombocythemia (ET). Int J Med Sci. 2016;13:85\u201391.","journal-title":"Int J Med Sci"},{"key":"2882_CR82","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1111\/bjh.16380","volume":"189","author":"A Tefferi","year":"2020","unstructured":"Tefferi A, Guglielmelli P, Lasho TL, Coltro G, Finke CM, Loscocco GG, et al. Mutation-enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera. Br J Haematol. 2020;189:291\u2013302.","journal-title":"Br J Haematol"},{"key":"2882_CR83","doi-asserted-by":"crossref","unstructured":"Gerds AT, Mesa RA, Burke JM, Grunwald MR, Stein BL, Squier P, et al. Association between elevated white blood cell counts and thrombotic events in polycythemia vera: analysis from REVEAL. Blood. 2024;143:1646\u201355.","DOI":"10.1182\/blood.2023020232"},{"key":"2882_CR84","doi-asserted-by":"publisher","first-page":"5171","DOI":"10.1182\/bloodadvances.2022007201","volume":"6","author":"M Sobas","year":"2022","unstructured":"Sobas M, Kiladjian JJ, Beauverd Y, Curto-Garcia N, Sadjadian P, Shih LY, et al. Real-world study of children and young adults with myeloproliferative neoplasms: identifying risks and unmet needs. Blood Adv. 2022;6:5171\u201383.","journal-title":"Blood Adv"},{"key":"2882_CR85","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s00277-017-3165-9","volume":"97","author":"P Boddu","year":"2018","unstructured":"Boddu P, Masarova L, Verstovsek S, Strati P, Kantarjian H, Cortes J, et al. Patient characteristics and outcomes in adolescents and young adults with classical Philadelphia chromosome-negative myeloproliferative neoplasms. Ann Hematol. 2018;97:109\u201321.","journal-title":"Ann Hematol"},{"key":"2882_CR86","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1038\/s41375-022-01528-x","volume":"36","author":"JJ Kiladjian","year":"2022","unstructured":"Kiladjian JJ, Klade C, Georgiev P, Krochmalczyk D, Gercheva-Kyuchukova L, Egyed M, et al. PROUD-PV Study Group. Long-term outcomes of polycythemia vera patients treated with ropeginterferon Alfa-2b. Leukemia. 2022;36:1408\u201311.","journal-title":"Leukemia"},{"key":"2882_CR87","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1002\/ajh.27002","volume":"98","author":"A Tefferi","year":"2023","unstructured":"Tefferi A, Barbui T. Polycythemia vera: 2024 update on diagnosis, risk-stratification, and management. Am J Hematol. 2023;98:1465\u201387.","journal-title":"Am J Hematol"},{"key":"2882_CR88","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.blre.2012.06.002","volume":"26","author":"T Barbui","year":"2012","unstructured":"Barbui T, Finazzi MC, Finazzi G. Front-line therapy in polycythemia vera and essential thrombocythemia. Blood Rev. 2012;26:205\u201311.","journal-title":"Blood Rev"},{"key":"2882_CR89","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1182\/blood-2012-02-366054","volume":"120","author":"F Passamonti","year":"2012","unstructured":"Passamonti F. How I treat polycythemia vera. Blood. 2012;120:275\u201384.","journal-title":"Blood"},{"key":"2882_CR90","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1182\/blood.2023022418","volume":"145","author":"MF McMullin","year":"2025","unstructured":"McMullin MF, Harrison CN. How I treat low-risk polycythemia vera patients who require cytoreduction. Blood. 2025;145:1717\u201323.","journal-title":"Blood"},{"key":"2882_CR91","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s11899-025-00752-3","volume":"20","author":"P Bose","year":"2025","unstructured":"Bose P, Xiao Z, Hasselbalch HC, Prchal JT, Duan M, Yacoub A, et al. Highlights from MPN Asia 2025: advances in molecular pathogenesis and therapeutic strategies in myeloproliferative neoplasms. Curr Hematol Malig Rep. 2025;20:9.","journal-title":"Curr Hematol Malig Rep"},{"key":"2882_CR92","doi-asserted-by":"publisher","first-page":"e196","DOI":"10.1016\/S2352-3026(19)30236-4","volume":"7","author":"H Gisslinger","year":"2020","unstructured":"Gisslinger H, Klade C, Georgiev P, Krochmalczyk D, Gercheva-Kyuchukova L, Egyed M, et al. Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study. Lancet Haematol. 2020;7:e196\u2013e208.","journal-title":"Lancet Haematol"},{"key":"2882_CR93","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1038\/s41375-023-02008-6","volume":"37","author":"H Gisslinger","year":"2023","unstructured":"Gisslinger H, Klade C, Georgiev P, Krochmalczyk D, Gercheva-Kyuchukova L, Egyed M, et al. PROUD-PV Study Group. Event-free survival in patients with polycythemia vera treated with ropeginterferon alfa-2b versus best available treatment. Leukemia. 2023;37:2129\u201332.","journal-title":"Leukemia"},{"key":"2882_CR94","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.70137","volume":"9","author":"JJ Kiladjian","year":"2025","unstructured":"Kiladjian JJ, Klade C, Georgiev P, Krochmalczyk D, Gercheva-Kyuchukova L, Egyed M, et al. PROUD-PV Study Group. Event-free survival in early polycythemia vera patients correlates with molecular response to ropeginterferon alfa-2b or hydroxyurea\/best available therapy (PROUD-PV\/CONTINUATION-PV). Hemasphere. 2025;9:e70137.","journal-title":"Hemasphere"},{"key":"2882_CR95","doi-asserted-by":"crossref","unstructured":"Knudsen TA, Hansen DL, Ocias LF, Bjerrum OW, Brabrand M, Christensen SF, et al. Final analysis of the Daliah trial: a randomised phase III trial of interferon-alpha2 versus hydroxyurea in patients with MPN. Blood. 2023;142:746.","DOI":"10.1182\/blood-2023-173127"},{"key":"2882_CR96","doi-asserted-by":"crossref","unstructured":"Barbui T, Vannucchi AM, De Stefano V, Carobbio A, Ghirardi A, Carioli G, et al. Ropeginterferon versus standard therapy for low-risk patients with polycythemia vera. NEJM Evid. 2023;2:EVIDoa2200335.","DOI":"10.1056\/EVIDoa2200335"},{"key":"2882_CR97","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s00277-023-05577-9","volume":"103","author":"T Barbui","year":"2024","unstructured":"Barbui T, Carobbio A, De Stefano V, Alvarez-Larran A, Ghirardi A, Carioli G, et al. Ropeginterferon phase 2 randomized study in low-risk polycythemia vera: 5-year drug survival and efficacy outcomes. Ann Hematol. 2024;103:437\u201342.","journal-title":"Ann Hematol"},{"key":"2882_CR98","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1002\/cncr.22026","volume":"107","author":"RT Silver","year":"2006","unstructured":"Silver RT. Long-term effects of the treatment of polycythemia vera with recombinant interferon-alpha. Cancer. 2006;107:451\u20138.","journal-title":"Cancer"},{"key":"2882_CR99","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/BF01737425","volume":"68","author":"S Sacchi","year":"1994","unstructured":"Sacchi S, Leono P, Liberati M, Riccardi A, Tabilio A, Tartoni P, et al. A prospective comparison between treatment with phlebotomy alone and interferon-alpha in patients with polycythemia vera. Ann Hematol. 1994;68:247\u201350.","journal-title":"Ann Hematol"},{"key":"2882_CR100","doi-asserted-by":"publisher","first-page":"2931","DOI":"10.1182\/blood.2021012743","volume":"139","author":"J Mascarenhas","year":"2022","unstructured":"Mascarenhas J, Kosiorek HE, Prchal JT, Rambaldi A, Berenzon D, Yacoub A, et al. A randomized phase 3 trial of interferon-\u03b1 vs hydroxyurea in polycythemia vera and essential thrombocythemia. Blood. 2022;139:2931\u201341.","journal-title":"Blood"},{"key":"2882_CR101","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1038\/s41375-022-01793-w","volume":"37","author":"RT Silver","year":"2023","unstructured":"Silver RT, Erdos K, Taylor E, Scandura JM, Abu-Zeinah G. Splenomegaly (SPML) in polycythemia vera (PV): its clinical significance and its relation to symptoms, post-polycythemic myelofibrosis (PPMF) and survival. Leukemia. 2023;37:691\u20134.","journal-title":"Leukemia"},{"key":"2882_CR102","doi-asserted-by":"publisher","first-page":"3534","DOI":"10.1200\/JCO.22.01935","volume":"41","author":"CN Harrison","year":"2023","unstructured":"Harrison CN, Nangalia J, Boucher R, Jackson A, Yap C, O\u2019Sullivan J, et al. Ruxolitinib versus best available therapy for polycythemia vera intolerant or resistant to hydroxycarbamide in a randomized trial. J Clin Oncol. 2023;41:3534\u201344.","journal-title":"J Clin Oncol"},{"key":"2882_CR103","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1002\/ajh.27400","volume":"99","author":"P Guglielmelli","year":"2024","unstructured":"Guglielmelli P, Mora B, Gesullo F, Mannelli F, Loscocco GG, Signori L, et al. Clinical impact of mutated JAK2 allele burden reduction in polycythemia vera and essential thrombocythemia. Am J Hematol. 2024;99:1550\u20139.","journal-title":"Am J Hematol"},{"key":"2882_CR104","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/ncomms12484","volume":"7","author":"AL Young","year":"2016","unstructured":"Young AL, Challen GA, Birmann BM, Druley TE. Clonal haematopoiesis harbouring AML-associated mutations is ubiquitous in healthy adults. Nat Commun. 2016;7:1\u20137.","journal-title":"Nat Commun"},{"key":"2882_CR105","doi-asserted-by":"publisher","first-page":"2490","DOI":"10.1182\/blood.2023020270","volume":"143","author":"M Usart","year":"2024","unstructured":"Usart M, Stetka J, Luque Paz D, Hansen N, Kimmerlin Q, Almeida Fonseca T, et al. Loss of Dnmt3a increases self-renewal and resistance to pegIFN-\u03b1 in JAK2-V617F-positive myeloproliferative neoplasms. Blood. 2024;143:2490\u2013503.","journal-title":"Blood"},{"key":"2882_CR106","doi-asserted-by":"publisher","first-page":"2707","DOI":"10.1182\/blood-2018-04-846220","volume":"132","author":"S Jacquelin","year":"2018","unstructured":"Jacquelin S, Straube J, Cooper L, Vu T, Song A, Bywater M, et al. Jak2V617F and Dnmt3a loss cooperate to induce myelofibrosis through activated enhancer-driven inflammation. Blood. 2018;132:2707\u201321.","journal-title":"Blood"},{"key":"2882_CR107","doi-asserted-by":"publisher","first-page":"2703","DOI":"10.1182\/blood-2018-11-883470","volume":"132","author":"RC Skoda","year":"2018","unstructured":"Skoda RC. Accelerating myelofibrosis through loss of Dnmt3a. Blood. 2018;132:2703\u20134.","journal-title":"Blood"},{"key":"2882_CR108","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1182\/blood.2024027528","volume":"146","author":"A Ghaith","year":"2025","unstructured":"Ghaith A, Erdos K, Lee N, Ganom Y, Klade C, Krejcy K, et al. DNMT3A mutations do not affect interferon-alpha treatment outcomes in polycythemia vera. Blood. 2025;146:123\u20136.","journal-title":"Blood"},{"key":"2882_CR109","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000485","volume":"4","author":"H Gisslinger","year":"2020","unstructured":"Gisslinger H, Klade C, Georgiev P, Krochmalczyk D, Gercheva-Kyuchukova L, Egyed M, et al. Ropeginterferon Alfa-2b: efficacy and safety in different age groups. Hemasphere. 2020;4:e485.","journal-title":"Hemasphere"},{"key":"2882_CR110","first-page":"1","volume":"00","author":"RK Pedersen","year":"2020","unstructured":"Pedersen RK, Andersen M, Knudsen TA, Sajid Z, Gudmand-Hoeyer J, Dam MJB, et al. Data-driven analysis of JAK2V617F kinetics during interferon alpha2 treatment of patients with polycythemia vera and related neoplasms. Cancer Med. 2020;00:1\u201313.","journal-title":"Cancer Med"},{"key":"2882_CR111","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1080\/10428194.2022.2070914","volume":"64","author":"K Abu-Zeinah","year":"2023","unstructured":"Abu-Zeinah K, Saadeh K, Silver RT, Scandura JM, Abu-Zeinah G. Excess mortality in younger patients with myeloproliferative neoplasms. Leuk Lymphoma. 2023;64:725\u20139.","journal-title":"Leuk Lymphoma"},{"key":"2882_CR112","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1038\/leu.2013.163","volume":"27","author":"A Tefferi","year":"2013","unstructured":"Tefferi A, Rumi E, Finazzi G, Gisslinger H, Vannucchi AM, Rodeghiero F, et al. Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia. 2013;27:1874\u201381.","journal-title":"Leukemia"},{"key":"2882_CR113","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1182\/blood.2019003347","volume":"135","author":"L Ronner","year":"2020","unstructured":"Ronner L, Podoltsev N, Gotlib J, Heaney ML, Kuykendall AT, O\u2019Connell C, et al. Persistent leukocytosis in polycythemia vera is associated with disease evolution but not thrombosis. Blood. 2020;135:1696\u2013703.","journal-title":"Blood"},{"key":"2882_CR114","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.3390\/ijms23031490","volume":"23","author":"D Markovi\u0107","year":"2022","unstructured":"Markovi\u0107 D, Maslovari\u0107 I, Djiki\u0107 D, \u010coki\u0107 VP. Neutrophil death in myeloproliferative neoplasms: shedding more light on neutrophils as a pathogenic link to chronic inflammation. Int J Mol Sci. 2022;23:1490.","journal-title":"Int J Mol Sci"},{"key":"2882_CR115","doi-asserted-by":"publisher","first-page":"3219","DOI":"10.1182\/blood-2011-11-394775","volume":"119","author":"HC Hasselbalch","year":"2012","unstructured":"Hasselbalch HC. Perspectives on chronic inflammation in essential thrombocythemia, polycythemia vera, and myelofibrosis: is chronic inflammation a trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer? Blood. 2012;119:3219\u201325.","journal-title":"Blood"},{"key":"2882_CR116","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.leukres.2012.10.020","volume":"37","author":"HC Hasselbalch","year":"2013","unstructured":"Hasselbalch HC. Chronic inflammation as a promotor of mutagenesis in essential thrombocythemia, polycythemia vera and myelofibrosis. A human inflammation model for cancer development? Leuk Res. 2013;37:214\u201320.","journal-title":"Leuk Res"},{"key":"2882_CR117","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.cytogfr.2013.01.004","volume":"24","author":"HC Hasselbalch","year":"2013","unstructured":"Hasselbalch HC. The role of cytokines in the initiation and progression of myelofibrosis. Cytokine Growth Factor Rev. 2013;24:133\u201345.","journal-title":"Cytokine Growth Factor Rev"},{"key":"2882_CR118","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1002\/cncr.30325","volume":"123","author":"RA Mesa","year":"2017","unstructured":"Mesa RA, Miller CB, Thyne M, Mangan J, Goldberger S, Fazal S, et al. Differences in treatment goals and perception of symptom burden between patients with myeloproliferative neoplasms (MPNs) and hematologists\/oncologists in the United States: findings from the MPN Landmark survey. Cancer. 2017;123:449\u201358.","journal-title":"Cancer"},{"key":"2882_CR119","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1111\/ejh.14019","volume":"111","author":"CN Solli","year":"2023","unstructured":"Solli CN, Chamat-Hedemand S, Elming H, Ngo A, Kjaer L, Skov V, et al. High JAK2V617F variant allele frequency is associated with coronary artery but not aortic valve calcifications in patients with Philadelphia-negative myeloproliferative neoplasms. Eur J Haematol. 2023;111:400\u20136.","journal-title":"Eur J Haematol"},{"key":"2882_CR120","doi-asserted-by":"publisher","first-page":"5825","DOI":"10.1182\/bloodadvances.2023010588","volume":"7","author":"MH Kristiansen","year":"2023","unstructured":"Kristiansen MH, Kj\u00e6r L, Skov V, Larsen MK, Ellervik C, Hasselbalch HC, et al. JAK2V617F mutation is highly prevalent in patients with ischemic stroke: a case-control study. Blood Adv. 2023;7:5825\u201334.","journal-title":"Blood Adv"},{"key":"2882_CR121","doi-asserted-by":"crossref","unstructured":"Yokokawa T, Misaka T, Kimishima Y, Wada K, Mitawa K, Sugimoto K, et al. Crucial role of hematopoietic JAK2V617F in the development of aortic aneurysms. Haematologica. 2021;106:1910-22.","DOI":"10.3324\/haematol.2020.264085"},{"key":"2882_CR122","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1161\/CIRCULATIONAHA.125.074002","volume":"152","author":"LM Obel","year":"2025","unstructured":"Obel LM, Skovbo JS, Diederichsen ACP, Thomassen M, Kj\u00e6r L, Larsen MK, et al. Aortic aneurysm risk and the somatic JAK2V617F mutation: insights from a multicenter, population-based cardiovascular screening study. Circulation. 2025;152:300\u201312.","journal-title":"Circulation"},{"key":"2882_CR123","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-26435-0","volume":"12","author":"Y Kimishima","year":"2021","unstructured":"Kimishima Y, Misaka T, Yokokawa T, Wada K, Ueda K, Sugimoto K, et al. Clonal hematopoiesis with JAK2V617F promotes pulmonary hypertension with ALK1 upregulation in lung neutrophils. Nat Commun. 2021;12:6177.","journal-title":"Nat Commun"},{"key":"2882_CR124","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1111\/ejh.13543","volume":"106","author":"A Ferrari","year":"2021","unstructured":"Ferrari A, Scandura J, Masciulli A, Krichevsky S, Gavazzi A, Barbui T. Prevalence and risk factors for pulmonary hypertension associated with chronic myeloproliferative neoplasms. Eur J Haematol. 2021;106:250\u20139.","journal-title":"Eur J Haematol"},{"key":"2882_CR125","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1182\/bloodadvances.2024013970","volume":"9","author":"AJ Gazda","year":"2025","unstructured":"Gazda AJ, Pan D, Erdos K, Abu-Zeinah G, Racanelli A, Horn EM, et al. High pulmonary hypertension risk by echocardiogram shortens survival in polycythemia vera. Blood Adv. 2025;9:1320\u20139.","journal-title":"Blood Adv"},{"key":"2882_CR126","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.blre.2018.03.007","volume":"32","author":"T Karantanos","year":"2018","unstructured":"Karantanos T, Moliterno AR. The roles of JAK2 in DNA damage and repair in the myeloproliferative neoplasms: opportunities for targeted therapy. Blood Rev. 2018;32:426\u201332.","journal-title":"Blood Rev"},{"key":"2882_CR127","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1182\/blood-2008-01-134114","volume":"112","author":"I Plo","year":"2008","unstructured":"Plo I, Nakatake M, Malivert L, de Villartay JP, Giraudier S, Villeval JL, et al. JAK2 stimulates homologous recombination and genetic instability: potential implications in the heterogeneity of myeloproliferative disorders. Blood. 2008;112:1402\u201312.","journal-title":"Blood"},{"key":"2882_CR128","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1056\/NEJMoa1701719","volume":"377","author":"S Jaiswal","year":"2017","unstructured":"Jaiswal S, Natarajan P, Silver AJ, Gibson CJ, Bick AG, Shvartz E, et al. Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. N Engl J Med. 2017;377:111\u201321.","journal-title":"N Engl J Med"},{"key":"2882_CR129","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1161\/CIRCRESAHA.117.312115","volume":"122","author":"JJ Fuster","year":"2018","unstructured":"Fuster JJ, Walsh K. Somatic mutations and clonal hematopoiesis: unexpected potential new drivers of age-related cardiovascular disease. Circ Res. 2018;122:523\u201332.","journal-title":"Circ Res"},{"key":"2882_CR130","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1161\/STROKEAHA.121.037388","volume":"53","author":"R Bhattacharya","year":"2022","unstructured":"Bhattacharya R, Zekavat SM, Haessler J, Fornage M, Raffield L, Uddin MM, et al. NHLBI trans-omics for precision medicine program, Natarajan P, Reiner AP. Clonal hematopoiesis is associated with a higher risk of stroke. Stroke. 2022;53:788\u201397.","journal-title":"Stroke"},{"key":"2882_CR131","doi-asserted-by":"publisher","first-page":"3132","DOI":"10.3390\/cancers12113132","volume":"12","author":"P Sadjadian","year":"2020","unstructured":"Sadjadian P, Wille K, Griesshammer M. Ruxolitinib-associated infections in polycythemia vera: review of the literature, clinical significance, and recommendations. Cancers. 2020;12:3132.","journal-title":"Cancers"},{"key":"2882_CR132","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.jaad.2021.10.004","volume":"86","author":"JQ Lin","year":"2022","unstructured":"Lin JQ, Li SQ, Li S, Kiamanesh EF, Aasi SZ, Kwong BY, et al. A 10-year retrospective cohort study of ruxolitinib and association with non-melanoma skin cancer in patients with polycythemia vera and myelofibrosis. J Am Acad Dermatol. 2022;86:339\u201344.","journal-title":"J Am Acad Dermatol"},{"key":"2882_CR133","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1182\/blood-2017-10-810739","volume":"132","author":"E Porpaczy","year":"2018","unstructured":"Porpaczy E, Tripolt S, Hoelbl-Kovacic A, Gisslinger B, Bago-Horvath Z, Casanova-Hevia E, et al. Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1\/2 inhibitor therapy. Blood. 2018;132:694\u2013706.","journal-title":"Blood"},{"key":"2882_CR134","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1182\/blood.2019000428","volume":"134","author":"A Yacoub","year":"2019","unstructured":"Yacoub A, Mascarenhas J, Kosiorek H, Prchal JT, Berenzon D, Baer MR, et al. Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea. Blood. 2019;134:1498\u2013509.","journal-title":"Blood"},{"key":"2882_CR135","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/bjh.17130","volume":"193","author":"AL S\u00f8rensen","year":"2021","unstructured":"S\u00f8rensen AL, Knudsen TA, Skov V, Kjaer L, Holm N, Ellervik C, et al. Smoking impairs molecular response and reduces overall survival in patients with chronic myeloproliferative neoplasms: a retrospective cohort study. Br J Haematol. 2021;193:83\u201392.","journal-title":"Br J Haematol"},{"key":"2882_CR136","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1182\/blood.2019001113","volume":"134","author":"S Cordua","year":"2019","unstructured":"Cordua S, Kjaer L, Skov V, Pallisgaard N, Hasselbalch HC, Ellervik C. Prevalence and phenotypes of JAK2 V617F and calreticulin mutations in a Danish general population. Blood. 2019;134:469\u201379.","journal-title":"Blood"},{"key":"2882_CR137","doi-asserted-by":"publisher","first-page":"e97","DOI":"10.3324\/haematol.2016.153973","volume":"102","author":"E Margolskee","year":"2017","unstructured":"Margolskee E, Krichevsky S, Orazi A, Silver RT. Evaluation of bone marrow morphology is essential for assessing disease status in recombinant interferon \u03b1-treated polycythemia vera patients. Haematologica. 2017;102:e97\u2013e99.","journal-title":"Haematologica"},{"key":"2882_CR138","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s40164-017-0090-5","volume":"6","author":"L Masarova","year":"2017","unstructured":"Masarova L, Yin CC, Cortes JE, Konopleva M, Borthakur G, Newberry KJ, et al. Histomorphological responses after therapy with pegylated interferon \u03b1-2a in patients with essential thrombocythemia (ET) and polycythemia vera (PV). Exp Hematol Oncol. 2017;6:30.","journal-title":"Exp Hematol Oncol"},{"key":"2882_CR139","doi-asserted-by":"publisher","first-page":"450","DOI":"10.3324\/haematol.2010.033191","volume":"96","author":"C Nielsen","year":"2011","unstructured":"Nielsen C, Birgens HS, Nordestgaard BG, Kjaer L, Bojesen SE. The JAK2 V617F somatic mutation, mortality and cancer risk in the general population. Haematologica. 2011;96:450\u20133.","journal-title":"Haematologica"},{"key":"2882_CR140","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aan8292","volume":"10","author":"O Wolach","year":"2018","unstructured":"Wolach O, Sellar RS, Martinod K, Cherpokova D, McConkey M, Chappell RJ, et al. Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasms. Sci Transl Med. 2018;10:eaan8292.","journal-title":"Sci Transl Med"},{"key":"2882_CR141","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00581-6","volume":"11","author":"P Guglielmelli","year":"2021","unstructured":"Guglielmelli P, Loscocco GG, Mannarelli C, Rossi E, Mannelli F, Ramundo F, et al. JAK2V617F variant allele frequency >50% identifies patients with polycythemia vera at high risk for venous thrombosis. Blood Cancer J. 2021;11:199.","journal-title":"Blood Cancer J"},{"key":"2882_CR142","doi-asserted-by":"crossref","unstructured":"Shapira Cohen T, Chodick G, Steinberg DM, Grossman E, Shohat M, Salomon O. JAK2V617F is a risk factor for Tia\/stroke in young patients. Thromb Haemost. 2022;122:1333\u201340.","DOI":"10.1055\/s-0042-1743470"},{"key":"2882_CR143","doi-asserted-by":"publisher","first-page":"e882","DOI":"10.1097\/HS9.0000000000000882","volume":"7","author":"K Wille","year":"2023","unstructured":"Wille K, Brouka M, Bernhardt J, R\u00fcfer A, Niculescu-Mizil E, Gotic M, et al. Outcome of 129 pregnancies in polycythemia vera patients: a report of the European LeukemiaNET. Hemasphere. 2023;7:e882.","journal-title":"Hemasphere"},{"key":"2882_CR144","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1182\/hematology.2024000578","volume":"2024","author":"J How","year":"2024","unstructured":"How J, Hobbs G. Pregnancy: MPN management before, during, and after pregnancy. Hematol Am Soc Hematol Educ Program. 2024;2024:541\u20136.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"2882_CR145","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1182\/blood.2023020729","volume":"143","author":"S Robinson","year":"2024","unstructured":"Robinson S, Ragheb M, Harrison C. How I treat myeloproliferative neoplasms in pregnancy. Blood. 2024;143:777\u201385.","journal-title":"Blood"},{"key":"2882_CR146","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s11899-014-0227-0","volume":"9","author":"G Barosi","year":"2014","unstructured":"Barosi G. An immune dysregulation in MPN. Curr Hematol Malig Rep. 2014;9:331\u20139.","journal-title":"Curr Hematol Malig Rep"},{"key":"2882_CR147","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/102476","volume":"2015","author":"HC Hasselbalch","year":"2015","unstructured":"Hasselbalch HC, Bj\u00f8rn ME. MPNs as inflammatory diseases: the evidence, consequences, and perspectives. Mediat Inflamm. 2015;2015:102476.","journal-title":"Mediat Inflamm"},{"key":"2882_CR148","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-00994-z","volume":"14","author":"MK Larsen","year":"2024","unstructured":"Larsen MK, Skov V, Kj\u00e6r L, Eickhardt-Dalb\u00f8ge CS, Knudsen TA, Kristiansen MH, et al. Neutrophil-to-lymphocyte ratio and all-cause mortality with and without myeloproliferative neoplasms\u2014a Danish longitudinal study. Blood Cancer J. 2024;14:28.","journal-title":"Blood Cancer J"},{"key":"2882_CR149","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1038\/s41375-018-0080-6","volume":"32","author":"T Tashi","year":"2018","unstructured":"Tashi T, Swierczek S, Kim SJ, Salama ME, Song J, Heikal N, et al. Pegylated interferon Alfa-2a and hydroxyurea in polycythemia vera and essential thrombocythemia: differential cellular and molecular responses. Leukemia. 2018;32:1830\u20133.","journal-title":"Leukemia"},{"key":"2882_CR150","doi-asserted-by":"crossref","unstructured":"Davidsen I, Larsen MK, L\u00f8ffler L, Skov V, Kj\u00e6r L, Knudsen T, et al. Statins enhance the efficacy of pegylated interferon-alpha2 in Philadelphia-negative chronic myeloproliferative neoplasms. Blood Adv. 2025;9:6189\u201398.","DOI":"10.1182\/bloodadvances.2025017016"},{"key":"2882_CR151","doi-asserted-by":"publisher","first-page":"LBA-4","DOI":"10.1182\/blood-2024-213103","volume":"144","author":"J Song","year":"2024","unstructured":"Song J, Kim SJ, Prchal J. Andean enriched NFKB1 haplotype reduces inflammation and improves response to ropeginterferon alfa-2b in polycythemia vera (PV) and essential thrombocythemia. Blood. 2024;144:LBA-4\u2013LB5.","journal-title":"Blood"},{"key":"2882_CR152","doi-asserted-by":"publisher","first-page":"6515","DOI":"10.1182\/blood-2011-04-348755","volume":"118","author":"H Frederiksen","year":"2011","unstructured":"Frederiksen H, Farkas DK, Christiansen CF, Hasselbalch HC, S\u00f8rensen HT. Chronic myeloproliferative neoplasms and subsequent cancer risk: a Danish population-based cohort study. Blood. 2011;118:6515\u201320.","journal-title":"Blood"},{"key":"2882_CR153","doi-asserted-by":"publisher","first-page":"e289","DOI":"10.1016\/S2352-3026(15)00092-7","volume":"2","author":"H Frederiksen","year":"2015","unstructured":"Frederiksen H, Farkas DK, Christiansen CF, Larsen TS, Hasselbalch HC, Stentoft J, et al. Survival of patients with chronic myeloproliferative neoplasms and new primary cancers: a population-based cohort study. Lancet Haematol. 2015;2:e289\u201396.","journal-title":"Lancet Haematol"},{"key":"2882_CR154","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1111\/ejh.12437","volume":"94","author":"HC Hasselbalch","year":"2015","unstructured":"Hasselbalch HC. Perspectives on the increased risk of second cancer in patients with essential thrombocythemia, polycythemia vera and myelofibrosis. Eur J Haematol. 2015;94:96\u20138.","journal-title":"Eur J Haematol"},{"key":"2882_CR155","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1016\/j.leukres.2014.07.006","volume":"38","author":"HC Hasselbalch","year":"2014","unstructured":"Hasselbalch HC. The platelet-cancer loop in myeloproliferative cancer. Is thrombocythemia an enhancer of cancer invasiveness and metastasis in essential thrombocythemia, polycythemia vera and myelofibrosis? Leuk Res. 2014;38:1230\u20136.","journal-title":"Leuk Res"},{"key":"2882_CR156","doi-asserted-by":"publisher","first-page":"e564","DOI":"10.1200\/JCO.2011.35.6238","volume":"29","author":"HC Hasselbalch","year":"2011","unstructured":"Hasselbalch HC, Kiladjian JJ, Silver RT. Interferon alfa in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms. J Clin Oncol. 2011;29:e564\u20135.","journal-title":"J Clin Oncol"},{"key":"2882_CR157","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.leukres.2005.12.018","volume":"30","author":"HC Hasselbalch","year":"2006","unstructured":"Hasselbalch HC, Riley CH. Statins in the treatment of polycythaemia vera and allied disorders: an antithrombotic and cytoreductive potential? Leuk Res. 2006;30:1217\u201325.","journal-title":"Leuk Res"},{"key":"2882_CR158","doi-asserted-by":"publisher","first-page":"3450","DOI":"10.1182\/bloodadvances.2023009784","volume":"7","author":"D Tuyet Kristensen","year":"2023","unstructured":"Tuyet Kristensen D, Kisbye \u00d8vlisen A, Hjort Kyneb Jakobsen L, Tang Severinsen M, Hannig LH, Starklint J, et al. Use of statins and risk of myeloproliferative neoplasms: a Danish nationwide case-control study. Blood Adv. 2023;7:3450\u20133457.","journal-title":"Blood Adv"},{"key":"2882_CR159","first-page":"576","volume":"368","author":"SF Nielsen","year":"2013","unstructured":"Nielsen SF, Nordestgaard BG, Bojesen SE. Statin use and reduced cancer-related mortality. N Engl J Med. 2013;368:576\u20137. Feb 7.","journal-title":"N Engl J Med"},{"key":"2882_CR160","doi-asserted-by":"crossref","unstructured":"Larsen MK, Skov V, Kj\u00e6r L, Eickhardt-Dalb\u00f8ge CS, Knudsen TA, Kristiansen MH, et al. The JAK2V617F and CALR mutations and risk of cancer, cardiovascular diseases, and all-cause mortality. J Intern Med. 2026;299:79\u201394.","DOI":"10.1111\/joim.70037"},{"key":"2882_CR161","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.yjmcc.2021.07.004","volume":"161","author":"CS Marnell","year":"2021","unstructured":"Marnell CS, Bick A, Natarajan P. Clonal hematopoiesis of indeterminate potential (CHIP): linking somatic mutations, hematopoiesis, chronic inflammation and cardiovascular disease. J Mol Cell Cardiol. 2021;161:98\u2013105.","journal-title":"J Mol Cell Cardiol"},{"key":"2882_CR162","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1007\/s40291-024-00737-7","volume":"28","author":"L Kjaer","year":"2024","unstructured":"Kjaer L, Skov V, Larsen MK, Kristiansen MH, Wienecke T, Cordua S, et al. Clonal hematopoiesis from a diagnostic perspective: 10 years of CHIP. Mol Diagn Ther. 2024;28:665\u20138.","journal-title":"Mol Diagn Ther"},{"key":"2882_CR163","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1182\/bloodadvances.2023012190","volume":"8","author":"HC Hasselbalch","year":"2024","unstructured":"Hasselbalch HC, Kristiansen MH, Kj\u00e6r L, Skov V, Larsen MK, Ellervik C, et al. CHIP-JAK2V617F, chronic inflammation, abnormal megakaryocyte morphology, organ failure, and multimorbidities. Blood Adv. 2024;8:681\u20132.","journal-title":"Blood Adv"},{"key":"2882_CR164","doi-asserted-by":"publisher","unstructured":"Hasselbalch HC, Skov V, Kjaer L, Knudsen TA, Eickhardt-Dalb\u00f8ge CS, Ellervik C, et al. The CHIP-clinic as the catalyst of preventive medicine. Front Hematol. 2024;3. https:\/\/doi.org\/10.3389\/frhem.2024.1459154","DOI":"10.3389\/frhem.2024.1459154"},{"key":"2882_CR165","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2020.100526","volume":"26","author":"C Liisborg","year":"2020","unstructured":"Liisborg C, Nielsen MK, Hasselbalch HC, S\u00f8rensen TL. Patients with myeloproliferative neoplasms and high levels of systemic inflammation develop age-related macular degeneration. EClinicalMedicine. 2020;26:100526.","journal-title":"EClinicalMedicine"},{"key":"2882_CR166","doi-asserted-by":"publisher","first-page":"866610","DOI":"10.3389\/fimmu.2022.866610","volume":"13","author":"AM Carnaz Sim\u00f5es","year":"2022","unstructured":"Carnaz Sim\u00f5es AM, Holmstr\u00f6m MO, Aehnlich P, Rahbech A, Radziwon-Balicka A, Zamora C, et al. Patients with myeloproliferative neoplasms harbor high frequencies of CD8 t cell-platelet aggregates associated with T cell suppression. Front Immunol. 2022;13:866610.","journal-title":"Front Immunol"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-02882-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-02882-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-02882-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T07:03:03Z","timestamp":1780470183000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-02882-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,8]]},"references-count":166,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["2882"],"URL":"https:\/\/doi.org\/10.1038\/s41375-026-02882-w","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,8]]},"assertion":[{"value":"21 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2026","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"In the originally published version of this article, the author affiliation was incorrect. This error has now been corrected.","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"RTS is Chair of the Data Safety Monitoring Board, SURPASS Study, PharmaEssentia, Inc. HCH has received research grants from Novartis and Pharmand Gmbh; advisory board AOP Orphan, Pharmand Gmbh, Incyte; personal fees from AOP Orphan and PharmaEssentia.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}